Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
129
228
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
Diagnos Laboratorium Utama PT Tbk
| Current Assets | 85.5B |
| Cash & Short-Term Investments | 4.5B |
| Receivables | 55.3B |
| Other Current Assets | 25.7B |
| Non-Current Assets | 220.2B |
| Long-Term Investments | 13B |
| PP&E | 202.1B |
| Intangibles | 1.6B |
| Other Non-Current Assets | 3.6B |
| Current Liabilities | 24.7B |
| Accounts Payable | 8.7B |
| Accrued Liabilities | 4.2B |
| Other Current Liabilities | 11.8B |
| Non-Current Liabilities | 87.5B |
| Long-Term Debt | 78.9B |
| Other Non-Current Liabilities | 8.5B |
Balance Sheet
Diagnos Laboratorium Utama PT Tbk
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
1 303
|
1 537
|
1 393
|
16 538
|
44 720
|
28 011
|
10 245
|
4 209
|
|
| Cash |
1 303
|
1 537
|
1 393
|
16 538
|
44 720
|
28 011
|
10 245
|
4 209
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
6 507
|
2 543
|
1 696
|
960
|
|
| Total Receivables |
4 978
|
8 365
|
7 451
|
81 273
|
73 939
|
49 455
|
45 252
|
48 889
|
|
| Accounts Receivables |
4 951
|
8 321
|
7 433
|
50 816
|
41 730
|
42 422
|
38 280
|
41 810
|
|
| Other Receivables |
27
|
44
|
18
|
30 457
|
32 209
|
7 033
|
6 972
|
7 079
|
|
| Inventory |
928
|
1 074
|
2 123
|
5 813
|
7 760
|
6 567
|
5 142
|
5 043
|
|
| Other Current Assets |
0
|
160
|
452
|
1 530
|
20 938
|
31 798
|
25 470
|
19 507
|
|
| Total Current Assets |
7 210
|
11 136
|
11 420
|
105 154
|
153 864
|
118 373
|
87 805
|
78 608
|
|
| PP&E Net |
493
|
9 144
|
16 365
|
20 108
|
87 107
|
109 219
|
164 248
|
202 426
|
|
| PP&E Gross |
493
|
9 144
|
16 365
|
20 108
|
87 107
|
109 219
|
164 248
|
202 426
|
|
| Accumulated Depreciation |
217
|
626
|
2 882
|
6 724
|
13 813
|
27 047
|
30 100
|
43 397
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
681
|
720
|
1 353
|
|
| Note Receivable |
709
|
4 084
|
28 138
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
8 445
|
12 951
|
12 951
|
|
| Other Long-Term Assets |
76
|
74
|
3 300
|
7 313
|
1 012
|
3 218
|
5 750
|
4 685
|
|
| Total Assets |
8 488
N/A
|
24 439
+188%
|
59 222
+142%
|
132 575
+124%
|
241 983
+83%
|
239 936
-1%
|
271 475
+13%
|
300 022
+11%
|
|
| Liabilities | |||||||||
| Accounts Payable |
2 545
|
1 952
|
2 035
|
15 825
|
4 524
|
3 078
|
6 090
|
9 551
|
|
| Accrued Liabilities |
13
|
140
|
393
|
140
|
3 125
|
1 556
|
3 178
|
4 116
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
113
|
5 224
|
563
|
767
|
2 966
|
4 140
|
4 255
|
5 691
|
|
| Other Current Liabilities |
561
|
3 463
|
6 125
|
13 880
|
16 013
|
1 718
|
920
|
2 250
|
|
| Total Current Liabilities |
3 232
|
10 779
|
9 116
|
30 612
|
26 628
|
10 492
|
14 444
|
21 606
|
|
| Long-Term Debt |
1 757
|
98
|
3 127
|
2 188
|
10 451
|
17 330
|
59 285
|
73 172
|
|
| Deferred Income Tax |
0
|
0
|
7
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
281
|
296
|
512
|
708
|
3 103
|
1 686
|
2 156
|
9 112
|
|
| Total Liabilities |
5 270
N/A
|
11 173
+112%
|
12 763
+14%
|
33 508
+163%
|
40 182
+20%
|
29 508
-27%
|
75 885
+157%
|
103 890
+37%
|
|
| Equity | |||||||||
| Common Stock |
250
|
1 000
|
25 000
|
25 000
|
31 250
|
31 250
|
31 250
|
31 250
|
|
| Retained Earnings |
2 979
|
12 244
|
21 519
|
74 205
|
132 509
|
145 173
|
131 518
|
132 265
|
|
| Additional Paid In Capital |
29
|
29
|
29
|
29
|
36 707
|
36 707
|
36 707
|
36 707
|
|
| Other Equity |
40
|
7
|
88
|
168
|
1 335
|
2 702
|
3 884
|
4 090
|
|
| Total Equity |
3 218
N/A
|
13 266
+312%
|
46 459
+250%
|
99 066
+113%
|
201 800
+104%
|
210 428
+4%
|
195 590
-7%
|
196 132
+0%
|
|
| Total Liabilities & Equity |
8 488
N/A
|
24 439
+188%
|
59 222
+142%
|
132 575
+124%
|
241 983
+83%
|
239 936
-1%
|
271 475
+13%
|
300 022
+11%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
1 250
|
1 250
|
1 250
|
1 000
|
1 250
|
1 250
|
1 250
|
1 250
|
|
